Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice TargetHot
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.